Description
Currently, the Genomtec Tumor project is in its early phase,
adopting SNAAT®-based solutions that could be used to quickly identify
neoplastic mutations or mutations that are of prognostic value in neoplastic
disease, as part of companion diagnostics (CDx) solution. The SNAAT® method
shall be adapted for near-patient testing of neoplastic mutations and will
allow quick implementation of personalized treatment. If combined with protein
markers, it may be possible to create a diagnostic platform for screening tests
and/or highly specific antigen identification in immunogenetic testing.
The early phase of the project, especially in comparison to
Genomtec ID and laboratory tests, makes the project dependent on the success of
other projects or acquisition of an industry partner, or obtaining grant
funding for further development of the project.
